PBS updates

Columvi (Glofitamab)

Glofitamab 10 mg/10 mL injection, 10 mL vial · INJECTION · PBS code 15228L

AUTHORITY_REQUIRED

What it costs

AU$5266.1 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2026-03-01.
  • • Repeats: 0.
  • • PBS program: IP.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)


Initial treatment (Cycle 1, Day 15)


Patient must be currently unable to receive treatment with CAR-T cell therapy for this condition; AND

Patient must be unsuitable for stem cell transplant; AND

Patient must have a WHO performance status of 2 or less; AND

Patient must have received or intend to receive a Cycle 1, Day 8 dose of glofitamab for this indication; AND

The treatment must be given in combination with gemcitabine and oxaliplatin for the first 8 cycles unless the patient has a contraindication/toxicity necessitating discontinuation of one or both chemotherapy components.

Glofitamab should be administered as an intravenous infusion according to the dose step-up schedule in Cycle 1 (2.5 mg on Day 8 and 10 mg on Day 15) leading to the recommended dosage of 30 mg on Day 1 of Cycles 2-12. Refer to the TGA approved Product Information.

Sponsor: Roche Products Pty Ltd ABN 70 000 132 865

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.